Drugs /

sacituzumab govitecan

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
sacituzumab govitecan
NCI Definition [1]:
An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for sacituzumab govitecan

Sacituzumab govitecan has been investigated in 26 clinical trials, of which 24 are open and 2 are closed. Of the trials investigating sacituzumab govitecan, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 8 are phase 1/phase 2 (7 open), 11 are phase 2 (11 open), and 4 are phase 3 (3 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for sacituzumab govitecan clinical trials.

Breast carcinoma, urothelial carcinoma, and invasive breast carcinoma are the most common diseases being investigated in sacituzumab govitecan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sacituzumab Govitecan
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sacituzumab Govitecan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sacituzumab govitecan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
rs7-sn38, anti-trop-2 antigen antibody-drug conjugate immu-132, hrs7-sn38 antibody drug conjugate, immu-132
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
TACSTD2
NCIT ID [1]:
C102783

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.